Antibody-dependent enhancement

Emergex Announces Positive Phase I Trial Data for DengueTcP™, Its Novel T Cell-Priming Immune Set-Point Candidate

Retrieved on: 
Tuesday, June 6, 2023

No treatment-related serious adverse events were reported, and the majority of adverse events were mild and transient.

Key Points: 
  • No treatment-related serious adverse events were reported, and the majority of adverse events were mild and transient.
  • From a safety perspective, both doses were considered acceptable for use in further trials.
  • These data demonstrate that our product platform has an acceptable safety profile and successfully mobilises viral-specific CD8+ T cells, which may elicit broad and long-term immune memory.
  • Follow-up of trial participants took place over a six-month period following first injection.

Kanazawa University research: Nanoscopic tool assesses alternative COVID-19 prevention

Retrieved on: 
Wednesday, January 18, 2023

KANAZAWA, Japan, Jan. 18, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Nano Letters how high-speed atomic force microscopy can be used to assess the effectivity of spike-neutralizing antibodies for preventing COVID-19.

Key Points: 
  • KANAZAWA, Japan, Jan. 18, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Nano Letters how high-speed atomic force microscopy can be used to assess the effectivity of spike-neutralizing antibodies for preventing COVID-19.
  • Vaccines against coronavirus disease 2019 (COVID-19) developed and produced during the COVID-19 pandemic offer a significant degree of protection.
  • Keesiang Lim from Kanazawa University and colleagues have now succeeded in video-imaging protein–SNAB interactions by means of high-speed atomic force microscopy (HS-AFM).
  • Researchers at Kanazawa University have in recent years developed HS-AFM further, so that it can be applied to study biochemical molecules and biomolecular processes in real-time.

Kanazawa University research: Nanoscopic tool assesses alternative COVID-19 prevention

Retrieved on: 
Wednesday, January 18, 2023

KANAZAWA, Japan, Jan. 18, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Nano Letters how high-speed atomic force microscopy can be used to assess the effectivity of spike-neutralizing antibodies for preventing COVID-19.

Key Points: 
  • KANAZAWA, Japan, Jan. 18, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Nano Letters how high-speed atomic force microscopy can be used to assess the effectivity of spike-neutralizing antibodies for preventing COVID-19.
  • Vaccines against coronavirus disease 2019 (COVID-19) developed and produced during the COVID-19 pandemic offer a significant degree of protection.
  • Keesiang Lim from Kanazawa University and colleagues have now succeeded in video-imaging protein–SNAB interactions by means of high-speed atomic force microscopy (HS-AFM).
  • Researchers at Kanazawa University have in recent years developed HS-AFM further, so that it can be applied to study biochemical molecules and biomolecular processes in real-time.

Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting

Retrieved on: 
Thursday, November 3, 2022

BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented a poster highlighting favorable AT-752 Phase 1 clinical data for the treatment of dengue fever at the American Society of Tropical Medicine & Hygiene (ASTMH) 2022 Annual Meeting in Seattle, Washington.

Key Points: 
  • Based on these data, we anticipate that AT-752 may have the potential to rapidly inhibit dengue virus replication across all serotypes (1-5).
  • The first study is a global, randomized, double-blind, placebo-controlled Phase 2 trial in adult patients with dengue virus infection.
  • AT-752, a novel, orally administered direct-acting antiviral derived from Ateas purine nucleotide prodrug platform was designed for the treatment and prophylaxis of dengue.
  • The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AT-752 for the treatment of dengue virus infection.

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue

Retrieved on: 
Monday, September 26, 2022

BOSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AT-752, a novel, orally administered, direct-acting antiviral for the treatment of dengue virus infection.

Key Points: 
  • AT-752, a novel, orally administered direct-acting antiviral derived from Ateas purine nucleotide prodrug platform was designed for the treatment and prophylaxis of dengue.
  • Dengue is the most prevalent mosquito-borne virus affecting up to 400 million people annually and is a substantial public health and economic burden worldwide.
  • Dengue causes a severe generalized illness with fever which may require hospitalization and is associated with mortality.
  • The FDA, together with other governmental and non-governmental agencies, recognize dengue as a substantial and growing global public health burden.

COVID Vaccine Mandate Will Not Protect Military Readiness, according to the Journal of American Physicians and Surgeons

Retrieved on: 
Monday, June 6, 2022

Current mRNA products create only a short-term immunity to the original viral strains, he writes, and cannot reliably prevent infection with the now dominant strains.

Key Points: 
  • Current mRNA products create only a short-term immunity to the original viral strains, he writes, and cannot reliably prevent infection with the now dominant strains.
  • Clinical trials were rushed and incomplete, he states.
  • As early as February 2021, some scientists were calling for a halt to the mass vaccination program.
  • The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS) , a national organization representing physicians in all specialties since 1943.

Negative Evidence for Antibody-Dependent Enhancement of COVID-19 Discussed in Journal of American Physicians and Surgeons

Retrieved on: 
Monday, March 28, 2022

The desired outcome of vaccination against a specific pathogen is to prevent illness or at least to prevent severe illness, she writes.

Key Points: 
  • The desired outcome of vaccination against a specific pathogen is to prevent illness or at least to prevent severe illness, she writes.
  • The lack of reports of VADE seems to be reassuring, but Dr. Orient asks, Does this constitute negative evidence?
  • The term negative evidence means evidence for a theory provided by the nonoccurrence or absence of something.
  • The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS) , a national organization representing physicians in all specialties since 1943.

Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant

Retrieved on: 
Sunday, December 12, 2021

These latest findings underscore that our combination antibody therapy holds up well against the Omicron variant that pose a significant public health threat worldwide," said Zhi Hong, Ph.D., Chairman and Chief Executive Officer of Brii Bio.

Key Points: 
  • These latest findings underscore that our combination antibody therapy holds up well against the Omicron variant that pose a significant public health threat worldwide," said Zhi Hong, Ph.D., Chairman and Chief Executive Officer of Brii Bio.
  • The in vitro tests against pseudovirus from independent labs have demonstrated the Omicron variant remains susceptible to neutralization by the amubarvimab/romlusevimab combination.
  • While there wassubstantial drop in activity for amubarvimab against the Omicron variant, romlusevimab was not impacted by the omicron variant.
  • Together, the combination therapy retains neutralizing activity against the Omicron variant, validating the importance of a combination mAb strategy to ensure clinical benefits forpatients at high risk for clinical progression.

Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit

Retrieved on: 
Wednesday, November 17, 2021

The recognition is for the R&D achievements of Brii Bio's investigational monoclonal neutralizing antibody combination therapy, BRII-196/BRII-198 ("combination BRII-196/BRII-198"), for the treatment of COVID-19.

Key Points: 
  • The recognition is for the R&D achievements of Brii Bio's investigational monoclonal neutralizing antibody combination therapy, BRII-196/BRII-198 ("combination BRII-196/BRII-198"), for the treatment of COVID-19.
  • In parallel, the company has submitted the Phase 3 interim data to China Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA).
  • The BioCentury-Bayhelix China Healthcare Awards celebrate outstanding individuals and companies for their achievement and contribution to the local healthcare ecosystem.
  • R&D Achievement of the Year recognizes one company for a scientific discovery in China with direct impact to drug R&D or a significant achievement in pharmaceutical development milestones.

Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease

Retrieved on: 
Friday, October 8, 2021

Similar efficacy rates were observed in participants initiating therapy early (0-5 days) and late (6-10 days), following symptom onset.

Key Points: 
  • Similar efficacy rates were observed in participants initiating therapy early (0-5 days) and late (6-10 days), following symptom onset.
  • This analysis also showed zero deaths in the treatment arm versus eight deaths in the placebo arm through day 28.
  • Following completion of the EUA submission, review and approval, Brii Bio plans to work closely with the FDA to coordinate on the next steps for full regulatory approval of combination BRII-196/BRII-198.
  • Data on the clinical efficacy of combination BRII-196/BRII-198 by variant type will also be evaluated as part of the study.